Immunoprecise(IPA) - 2021 Q1 - Quarterly Report

Exhibit 99.2 IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three months ended July 31, 2021 and 2020 | | | Three months ended July 31, | | | --- | --- | --- | --- | | | | 2021 | 2020 | | (in thousands, except share data) | Note | $|$ | | REVENUE | | 4,588 | 3,765 | | COST OF SALES | | 2,082 | 1,355 | | GROSS PROFIT | | 2,506 | 2,410 | | EXPENSES | | | | | Advertising | | 163 | 33 | | Amortization and depreciation | 8, 9 | 670 | 678 | | Bad debt expense (recovery ...